On the stock market since 2019, it operates in the world of health and science. It has 8 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 42% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades 58% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 67% a year on average.
Sales run at $10.8M a year. A small number, but proof the product has real buyers.
A loss of $193.4M against $10.8M in annual sales.
The stock sits at $0.26. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, KDEVF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: KDEVF is a high-risk stock — not yet profitable, and its future rides on its product catching on.